Handelsavisen
prelaunch
Companies Healthcare 4107.TWO
41
4107.TWO TPEx Medical Equipment, Supplies & Distribution

Bioteque Corp

$113,50
Open in Charts → Attach watcher ⌖
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
7,9B TWD
P/E
EV / Rev
Div yield
4,33 %
Op margin
31,4 %
ROE
14,9 %
Net margin
25,2 %
Debt / equity
0,17
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Bioteque Corp is a medical equipment and supplies company that generates revenue through the distribution and sale of healthcare products and services.

Business. Bioteque Corp (4107.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Premium Exchange (TPEx).

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
14,9 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4107.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4107.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Bioteque Corp (4107.TWO) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue through the sale of products, though specific operating segments and geographic breakdowns are not disclosed. Headquartered in Taiwan, the company is primarily listed on the Taiwan Premium Exchange (TPEx).

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    Bioteque Corp maintains a strong capital structure with a debt-to-equity ratio of 0.17, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 4.27, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints.

    In terms of profitability, Bioteque Corp demonstrates a return on equity (ROE) of 14.95% and a return on assets (ROA) of 11.57%, both of which are strong indicators of efficient capital utilization and asset management. The company's operating margin, calculated as operating income divided by revenue, is 31.4%, which is a key metric for assessing operational efficiency in the medical equipment and supplies industry.

    Geographically and segment-wise, the company's revenue concentration is not explicitly detailed in the available data. However, the company's exposure to the healthcare services and equipment sector is significant, with no clear indication of diversification across multiple geographic regions or product lines.

    The company's growth trajectory is supported by a positive free cash flow of 302.8 million TWD and a capital expenditure of -57.2 million TWD, indicating that it is generating more cash than it is investing in new capital assets. The outlook for the current fiscal year suggests continued growth, although specific numeric deltas for the next fiscal year are not provided in the available data.

    Risk factors for Bioteque Corp include a medium liquidity risk and a low dilution risk. The company's net cash position being negative after subtracting total debt is a notable risk factor that could affect its ability to meet short-term obligations. There is no indication of dilution potential in the basic shares outstanding, as the number of basic and diluted shares is the same.

    Recent events and filings have not been detailed in the available data, so there is no specific information on recent corporate actions or regulatory changes that could impact the company's operations or financial performance.

    Key takeaways
    • Bioteque Corp has a strong ROE of 14.95% and ROA of 11.57%, indicating efficient capital and asset utilization.
    • The company's liquidity position is medium, with a current ratio of 4.27, but its net cash position is negative after subtracting total debt.
    • The company's debt-to-equity ratio of 0.17 suggests a conservative capital structure with low reliance on debt.
    • Bioteque Corp generates a positive free cash flow of 302.8 million TWD, supporting its growth and operational flexibility.
    • The company's risk assessment indicates a low dilution risk and a medium liquidity risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $113,50
    Market cap
    $7.97B
    Enterprise value
    $8.57B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    12.9x
    P / B
    2.2x
    P / Tangible book
    2.2x
    Tangible book
    $3.61B
    Net cash
    -$597.4M
    Current ratio
    4.3
    Debt / equity
    0.2
    ROA
    11.6%
    ROE
    14.9%
    Cash conversion
    123.0%
    CapEx / revenue
    -2.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy0
    Buy0
    Hold1
    Sell0
    Strong sell0

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin31,4 %Above P75
    Net Margin25,2 %Above P75
    ROE14,9 %Above P75
    Capex / Rev-2,7 %Above median
    D/E0,17Above median
    Cash Conv1,23Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • Bioteque Corp Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4107.TWOCanonical
    TPEx · TWD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage